TREATING MEDICINE FOR FULMINANT HEPATITIS AND ACUTE HEPATIC INSUFFICIENCY

摘要

PURPOSE: To provide a treating medicine for fulminant hepatitis containing a platelet activation factor-antagonistic agent to inhibit hepatic cells from being necrosed over a wide range by fulminant hepatitis and prevent hepatic insufficiency. ;CONSTITUTION: The objective medicine contains platelet activation factor-(PAF) antagonist. As an PAF antagonist, is recommendably used (+)-cis-3,5- dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride, 4-(2-chlorophenyl)-9- methyl-2-[3-(4-morpholinyl)-3-propan-1-yl]-6H-thieno[3,2-f] [1,2,4] triazolo [4,3- diazepin or the like. The dose of the PAF antagonist is preferably 10-50mg/adult every oral administration. In the case of intravenous or intramuscular administration, 1-25mg/adult every administration is preferred and it is given 1-4 times every day.;COPYRIGHT: (C)1995,JPO